InMed FY2024 net loss $7.7M; revenue up 11% to $4.6M; cash $6.6M

InMed Pharmaceuticals Inc.

2025-Q1 EPS reported -$2.71 revenue$1,264,638

Net loss of $7.7M vs $7.9M prior year; diluted EPS loss $1.01 vs $3.25.
Revenue from BayMedica segment $4.6M, up 11% YoY; gross profit $1.1M.
Cash, equivalents, and short-term investments $6.6M at June 30, 2024.
R&D and patent expenses $3.8M; G&A $5.3M, down from $5.8M.
Pipeline update: INM-901 Alzheimer's program advancing; INM-089 dry AMD preclinical data positive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.